Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life

Pediatrics

Volumn 121, Issue 3, 2008, Pages 562-569

  Adamkiewicz, Thomas V ^a   Silk, Benjamin J ^b   Howgate, James ^c   Baughman, Wendy ^c   Strayhorn, Gregory ^a   Sullivan, Kevin ^b   Farley, Monica M ^c  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

7 valent pncompc vaccine; Conjugate vaccine; Hemoglobin sc disease; Herd immunity; Sepsir; Sickle cell anemia; Streptococcus pneumoniae

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN S; PENICILLIN G; PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CHILD; HEMOGLOBIN SC DISEASE; HEMOGLOBINOPATHY; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INVASIVE PNEUMOCOCCAL DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SEROTYPING; SICKLE CELL ANEMIA; STREPTOCOCCUS PNEUMONIA; SURVIVAL; UNITED STATES; AGE; ANALYSIS OF VARIANCE; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HERD IMMUNITY; IMMUNIZATION; IMMUNOLOGY; INFANT; MALE; PRESCHOOL CHILD; PROBABILITY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; STATISTICS; STREPTOCOCCUS INFECTION; VACCINATION;

AGE FACTORS; ANALYSIS OF VARIANCE; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GEORGIA; HUMANS; IMMUNITY, HERD; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; MALE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROBABILITY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; VACCINATION;

EID: 40949107353     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-0018     Document Type: Article

References (39)

1. Powars D, Overturf G, Weiss J, Lee S, Chan L. Pneumococcal septicemia in children with sickle cell anemia: changing trend of survival. JAMA. 1981;245(18):1839-1842
2. Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr. 1986;109(4):579-585
3. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314(25):1593-1599
4. Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K. Strep- toeoccus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease. J Pediatr Hematol Oncol 1. 2002;24(6):470-472
5. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23- valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;I43(4):438-444
6. Berkovitch M, Papadouris D, Shaw D, Onuaha N, Dias C, Olivieri NF. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. Br J Clin Pharmacol 1998;45(6):605-607
7. Elliott V, Morgan S, Day S, Mollerup LS, Wang W. Parental health beliefs and compliance with prophylactic penicillin administration in children with sickle cell disease. J Pediatr Hema- tol Oncol. 2001;23(2):112-116
8. Teach SJ, Lillis KA, Grossi M. Compliance with penicillin prophylaxis in patients with sickle cell disease. Arch Pediatr Adolesc Med. I998;152(3):274-278
9. Sox CM, Cooper WO, Koepsell TD, DiGiuseppe DL, Christakis DA. Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease. JAMA. 2003;290(8): 1057-1061
10. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000;106(2): 362-366
11. Advisory Committee on immunization Practices. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-9):l-35
12. Bjornson AB, Falletta JM, Verter JJ, et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr. 1996;129(6): 828-835
13. Rao SP, RajkumarK, Schiffman G, Desai N, Unger C, Miller ST. Anti-pneumococcal antibody levels three to seven years after first booster immunization in children with sickle cell disease, and after a second booster. J Pediatr. 1995;127(4):590-592
14. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3): 187-195
15. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(]4):1341-1348
16. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double- blind, placebo-controlled trial. Lancet. 2005;365(9465): 1139-1146
17. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein- polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18): 1737-1746
18. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004;291 (18):2197-2203
19. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005; 294(1 6):2043-2051
20. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455-1463
21. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis. 2006; 193(11): 1487-1494
22. Musher DM. Pneumococcal vaccine: direct and indirect ("herd") effects. N Engl J Med. 2006;354(14):1522-1524
23. Schuchat A, Hilger T, Zell E, et al. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis. 2001;7(l):92-99
24. Papadea C, Eckman JR, Kuebnert RS, Piatt AF. Comparison of liquid and dried blood for neonatal hemoglobinopathy screening: laboratory and programmatic issues. Pediatrics. 1994; 93(3):427-432
25. Serjeant GR, Serjeant B. Sickle Cell Disease. Oxford, United Kingdom: Oxford University Press; 2001:456-471
26. National Heart, Lung, Blood Institute. The Management of Sickle Cell Disease. Bethesda, MD: National Heart, Lung, Blood Institute; 2002
27. Pickering LK, ed. Red Book: Report of the Committee on Infectious Disease. Elk Grove Village, IL: American Academy of Pediatrics; 2003:26-31
28. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility 'Testing: Twelfth Informational Supplement. NCCLS document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002
29. Serjeant GR, Serjeant B. Sickle Cell Disease. Oxford, United Kingdom: Oxford University Press; 2001:31-40
30. Hennekens CH. Epidemiology in Medicine. Boston, MA: Little, Brown and Company; 1987:77-96
31. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. Hoboken, NJ: Wiley; 1999:304
32. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84(408):1074-1078
33. Halasa NB, Shanka SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428-1433
34. Mahon BE, Hsu K, Karumuri S, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine. 2006;24(14):2514-2520
35. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495-1502
36. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995;333(8):481-486
37. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343(26):1917-1924
38. Bodenheimer T. Wagner EH. Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288(14): 1775-1779
39. Bodenheimer T. Wagner EH. Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002;288(15):1909-1914